James has over a decade of experience in the healthcare industry, supporting global pharmaceutical and biotech companies in addressing complex strategic challenges. He brings broad consulting expertise across portfolio and brand strategy, competitive strategy, and lifecycle management, with particularly deep experience in Loss of Exclusivity (LOE) planning. James has led the development and implementation of LOE planning frameworks and tools, and offers strong insight into post‑LOE market dynamics across a wide range of global geographies.

Before joining Align in 2019, James was Global Market Research & Portfolio Analyst for the health sector of Johnson Matthey. In this role, he was responsible for conducting product & market assessments, including financial modeling, to help shape the strategic direction of the company’s generic pipeline.

Earlier in his career, James worked as a Productivity Consultant with the UK NHS, before spending over three years at Sociable Pharma (now part of GlobalData) supporting many of the top 20 pharmaceutical companies with competitive intelligence, and delivering syndicated and custom research and analysis projects, with a particular focus on metabolic and infectious diseases.

James holds an MSc in Drug Discovery & Translational Biology from the University of Edinburgh and a BSc in Cell Biology from the University of St Andrews.

Outside of work, James is an avid sports enthusiast and enjoys running, playing football and golf, and regularly competes in fitness racing.